Humanigen: Lenzilumab Combination Trial In Hospitalized COVID-19 Patients Fails To Meet Main Goal

(RTTNews) - Humanigen Inc. (HGEN) said Tuesday that ACTIV-5/BET-B trial, which evaluated lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients, did not achieve statistical significance on the primary endpoint.

The primary endpoint was defined as the proportion of patients with baseline CRP<150 mg/L and age<85 years, alive and without mechanical ventilation through Day 29.

The data also showed a non-significant trend toward a reduction in mortality in the overall patient population [HR 0.72]. There were no new safety signals attributed to lenzilumab in the ACTIV-5/BET-B study.

Humanigen said it received the preliminary data from NIH/NIAID study of Lenzilumab in ACTIV-5/BET-B trial.

"... while the ACTIV-5/BET-B study showed signs of a clinical effect, the benefit demonstrated was not able to confirm the positive results we saw in our Phase 3 LIVE-AIR study," said Cameron Durrant, Chairman and Chief Executive Officer, Humanigen.

For More Such Health News, visit rttnews.com